Literature DB >> 21995399

Vemurafenib in melanoma with BRAF V600E mutation.

Stéphane Dalle, Nicolas Poulalhon, Luc Thomas.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21995399     DOI： 10.1056/NEJMc1108651

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  20 in total

Review 1.  Cutaneous toxicities of new treatments for melanoma.

Authors:  A Boada; C Carrera; S Segura; H Collgros; P Pasquali; D Bodet; S Puig; J Malvehy
Journal:  Clin Transl Oncol       Date:  2018-05-24       Impact factor: 3.405

2.  Dormant melanomas or changing nevi?

Authors:  Giuseppe Argenziano; Aimilios Lallas; Caterina Longo; Elvira Moscarella; Margherita Raucci; Iris Zalaudek
Journal:  J Invest Dermatol       Date:  2014-05       Impact factor: 8.551

Review 3.  Managing the skin toxicities from new melanoma drugs.

Authors:  John C Mavropoulos; Timothy S Wang
Journal:  Curr Treat Options Oncol       Date:  2014-06

4.  NRAS Q61R and BRAF G466A mutations in atypical melanocytic lesions newly arising in advanced melanoma patients treated with vemurafenib.

Authors:  Vishwas Parekh; Joseph Sobanko; Christopher J Miller; Giorgos Karakousis; Wei Xu; Richard Letrero; Rosalie Elenitsas; Xiaowei Xu; David E Elder; Ravi Amaravadi; Lynn M Schuchter; Katherine L Nathanson; Melissa A Wilson; Emily Y Chu
Journal:  J Cutan Pathol       Date:  2018-12-27       Impact factor: 1.587

5.  Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition.

Authors:  Lisa Zimmer; Uwe Hillen; Elisabeth Livingstone; Mario E Lacouture; Klaus Busam; Richard D Carvajal; Friederike Egberts; Axel Hauschild; Mohammed Kashani-Sabet; Simone M Goldinger; Reinhard Dummer; Georgina V Long; Grant McArthur; André Scherag; Antje Sucker; Dirk Schadendorf
Journal:  J Clin Oncol       Date:  2012-05-21       Impact factor: 44.544

6.  Analysis of dermatologic events in vemurafenib-treated patients with melanoma.

Authors:  Mario E Lacouture; Madeleine Duvic; Axel Hauschild; Victor G Prieto; Caroline Robert; Dirk Schadendorf; Caroline C Kim; Christopher J McCormack; Patricia L Myskowski; Olivia Spleiss; Kerstin Trunzer; Fei Su; Betty Nelson; Keith B Nolop; Joseph F Grippo; Richard J Lee; Matthew J Klimek; James L Troy; Andrew K Joe
Journal:  Oncologist       Date:  2013-03-01

7.  Appearance of New Vemurafenib-associated Melanocytic Nevi on Normal-appearing Skin: Case Series and a Review of Changing or New Pigmented Lesions in Patients with Metastatic Malignant Melanoma After Initiating Treatment with Vemurafenib.

Authors:  Philip R Cohen; Agop Y Bedikian; Kevin B Kim
Journal:  J Clin Aesthet Dermatol       Date:  2013-05

Review 8.  Paradoxical oncogenesis--the long-term effects of BRAF inhibition in melanoma.

Authors:  Geoffrey T Gibney; Jane L Messina; Inna V Fedorenko; Vernon K Sondak; Keiran S M Smalley
Journal:  Nat Rev Clin Oncol       Date:  2013-05-28       Impact factor: 66.675

Review 9.  Genetics of melanocytic nevi.

Authors:  Mi Ryung Roh; Philip Eliades; Sameer Gupta; Hensin Tsao
Journal:  Pigment Cell Melanoma Res       Date:  2015-11       Impact factor: 4.693

Review 10.  Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials.

Authors:  Maria Schwaederle; Melissa Zhao; J Jack Lee; Alexander M Eggermont; Richard L Schilsky; John Mendelsohn; Vladimir Lazar; Razelle Kurzrock
Journal:  J Clin Oncol       Date:  2015-08-24       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.